AOD-9604 raises a handful of sensible questions. This page answers them in order, starting with the fundamentals and moving to applications.
Reviewed 2025-12-19. Anything still debated is marked as such rather than presented as settled.
AOD-9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It corresponds to residues 176-191 of the 191-amino-acid hGH sequence. The fragment is not the full hormone and lacks the receptor-binding region associated with growth and metabolic effects of hGH. Researchers developed it to isolate a specific portion of hGH for study. Its exact sequence and length are often stated in peptide catalogs and patents.
The peptide is frequently described as a growth hormone fragment, although it is chemically distinct from full-length hGH. AOD-9604 contains 16 amino acids and includes two cysteine residues that can form an intramolecular disulfide bond. In solution, this structural feature can influence folding, aggregation, and stability. Published descriptions sometimes call it hGH 176-191 or AOD9604, with spacing and capitalization varying. Such naming differences can complicate literature searches, database entries, and product verification.
Researchers have studied the fragment in cell and animal models to understand its metabolic actions. Some experiments report effects on fat breakdown and fat storage pathways, but the underlying mechanism remains incompletely defined. AOD-9604 does not appear to stimulate the same broad growth hormone receptor signaling as full-length hGH. Whether its observed activities arise from direct receptor interactions or downstream metabolic changes is an open question. Results from different assays are not always consistent.
AOD-9604 is a synthetic peptide whose structure corresponds to a C-terminal segment of human growth hormone. It is often described as hGH fragment 176-191, a 16-amino-acid sequence. The peptide was designed to isolate a region of hGH associated with fat metabolism while avoiding the full hormone's growth-promoting actions. Laboratory and commercial materials typically present it as a lyophilized powder for research use. Its identity is defined by amino acid sequence, not by a single brand.
The fragment includes residues that can form an internal disulfide bond between two cysteine positions. This structural feature can influence how the peptide folds and how stable it is in solution. AOD-9604 differs from full-length hGH in size and receptor interactions; it does not contain the entire growth hormone sequence. Published descriptions sometimes use slightly different residue numbering, so sequence information should be checked against primary sources. The molecule is small compared with intact hGH, which affects analytical detection and purification approaches.
Interest in AOD-9604 arose from attempts to separate metabolic effects from growth effects attributed to hGH. Early work explored whether the fragment could influence lipolysis or fat oxidation without promoting growth. Those questions remain partly unresolved because human data are limited and results have varied across studies. The peptide is not a hormone replacement for hGH and is not equivalent to hGH in clinical use. Its research history includes both laboratory studies and commercial marketing claims that are not the same as regulatory approval.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic peptide | Derived from a fragment of human growth hormone |
| Sequence basis | hGH residues 176-191 | Commonly described as a 16-amino-acid fragment |
| Appearance | White to off-white powder | Typical for lyophilized research peptides |
| Solubility | Soluble in water or aqueous buffer | Exact solubility depends on pH and purity |
| Common synonyms | AOD9604; hGH 176-191 | Spelling and punctuation vary across sources |
The compound has been studied as a potential treatment for obesity and related metabolic conditions. Published trials have examined changes in body weight, fat mass, and safety markers over limited durations. Results have been mixed or modest, and no large-scale outcome trials are established. Regulatory agencies in several countries have not approved it as a therapeutic drug. Some commercial products have been marketed outside regulated pharmaceutical channels, which raises questions about quality and claims.
In the scientific literature, AOD-9604 appears in reviews of growth hormone fragments and in discussions of peptide-based metabolic research. Some sources distinguish it from growth hormone itself, while others group it with compounds marketed for weight management. The evidence base is small compared with approved obesity medications. Questions about long-term efficacy and clinical relevance remain open, and independent replication of key findings is limited. Most published reports are early-stage and exploratory.
AOD-9604 is listed as a prohibited substance in sport by the World Anti-Doping Agency. It falls under the peptide hormones, growth factors, related substances, and mimetics class on the prohibited list. Anti-doping organizations treat its presence in an athlete's sample as an adverse finding unless a therapeutic use exemption applies. The prohibition reflects concerns about performance enhancement in competitive settings and the difficulty of distinguishing exogenous peptide use from endogenous hormone fragments.
Detection of AOD-9604 in biological samples relies on analytical techniques capable of distinguishing a small synthetic peptide from related endogenous sequences. Liquid chromatography coupled with tandem mass spectrometry is commonly used for confirmatory analysis. Sample preparation may involve immunoaffinity enrichment or solid-phase extraction to concentrate the peptide. Because the molecule is small and may be present at low concentrations, assay sensitivity and specificity are ongoing analytical challenges. Laboratories also validate methods against reference materials when available.
Regulatory interest in AOD-9604 increased after high-profile anti-doping cases involving peptide products. In some cases, the substance was supplied under alternative names or in compounded preparations, complicating traceability. Sports tribunals and anti-doping panels have discussed whether the peptide was explicitly banned at the time of use, leading to clarifications by the World Anti-Doping Agency. For consumers and researchers, the legal status can vary by jurisdiction, and products marketed as research chemicals may lack independent quality verification.
(2026) provide age estimates for Pleistocene rock art (hand stencils, human figures and non-figurative, geometric motifs) from southeastern Sulawesi (Indonesia) and determine the calcite overlying a hand stencil from Liang Metanduno on Muna Island to be at least 67,800 years old, representing the oldest demonstrated minimum-age constraints for parietal art worldwide reported to date, and interpreted as the oldest known archaeological evidence for the presence of Homo sapiens in Wallacea. Ruff et al. (2026) describe a Late Pleistocene human femur from Wajak (Java, Indonesia), calculate body mass and stature of the studied individual and compare them with data on other Late Pleistocene individuals from East Asia, reporting evidence of greater body mass and relative body breadth in individuals from higher latitudes. Borreggine et al. (2026) reconstruct likely timing and paths of early human migration from Sundaland into Sahul, and find northern routes of migration to be more likely than southern when changes of sea level and ocean currents are taken into account. Evidence of exploitation of a broad range of resources by humans occupying the Inumaki Cave on Biak (Indonesia) during the Last Glacial Maximum is presented by Tolla et al. (2026). Brumm et al. (2026) identify dental pathologies in late Pleistocene and Holocene human remains from the Leang Bulu Bettue and Leang Cappalombo 1 sites (Sulawesi, Indonesia) interpreted as consistent with use of areca nuts as drugs by the studied individuals through sucking on intact nuts. Allen et al.
=== Surgery === The surgery to repair the anterior vaginal wall may be combined with other procedures that will repair the other points of pelvic organ support such as anterior-posterior repair and anterior colporrhaphy. Treatment of cystocele often accompanies the more invasive hysterectomy. Since the failure rate in cystocele repair remains high, additional surgery may be needed. Women who have surgery to repair a cystocele have a 17% chance of needing another operation within the next ten years. The surgical treatment of cystocele will depend on the cause of the defect and whether it occurs at the top (apex), middle, or lower part of the anterior vaginal wall. The type of surgery will also depend on the type of damage that exists between supporting structures and the vaginal wall. One of the most common surgical repairs is colporrhaphy. This surgical procedure consists of making a longitudinal folding of the vaginal tissue, suturing it into place and creating a stronger point of resistance to the intruding bladder wall. Surgical mesh is sometimes used to strengthen the anterior vaginal wall. It has a 10–50% failure rate. In some cases a surgeon may choose to use surgical mesh to strengthen the repair. During surgery, the repair of the vaginal wall consists of folding over and then suturing the existing tissue between the vagina and bladder to strengthen it. This tightens the layers of tissue to promote the replacement of the pelvic organs into their normal place. The surgery also provides more support for the bladder.
is the molecular mass. In general, however, the viscosity of a system depends in detail on how the molecules constituting the system interact, and there are no simple but correct formulas for it. The simplest exact expressions are the Green–Kubo relations for the linear shear viscosity or the transient time correlation function expressions derived by Evans and Morriss in 1988. Although these expressions are each exact, calculating the viscosity of a dense fluid using these relations currently requires the use of molecular dynamics computer simulations. Somewhat more progress can be made for a dilute gas, as elementary assumptions about how gas molecules move and interact lead to a basic understanding of the molecular origins of viscosity. More sophisticated treatments can be constructed by systematically coarse-graining the equations of motion of the gas molecules. An example of such a treatment is Chapman–Enskog theory, which derives expressions for the viscosity of a dilute gas from the Boltzmann equation.
Sources: en.wikipedia.org
Lebanese historian Philip K. Hitti commented on the relationship between the Druze and Christians in Lebanon, noting: "Folty Comte, a French scholar, was astonished by the remarkable similarity between the Druze and the Maronites (Christians) in their way of life, system of governance, dialect, customs, and public morals. Druze and Maronite families coexist harmoniously, and sometimes Maronites accompany their Druze neighbors to church". According to Hitti, the Druze believe in the efficacy of holy water blessed by a priest, and occasionally, if a missionary persists in evangelizing the Druze, they may accept the sacrament of baptism. Maretti, an Italian monk who visited the region in 1760, just before Folty's arrival, observed that the Druze show genuine affection and respect for Christians and their religion. He also noted that Druze pray in Greek Orthodox churches as they do in Turkish mosques. Historian Ray Jabre Mouawad observes that during the Ottoman period, there existed religious symbiosis between the Druze and Christians in Mount Lebanon. This period saw numerous cultural interactions, leading to shared symbols, the veneration of common saints, and the adoption of common terminology to refer to God. Evidence of these interactions can be found in the palaces and mausoleums of Druze leaders, as well as in Maronite and Greek Orthodox churches. According to scholar Pierre-Yves Beaurepaire, due to the Christian influence on the Druze faith, two Christian saints become the Druze's favorite venerated figures: Saint George and the Prophet Elijah.
The committee was composed of 16 experts, including leaders in clinical medicine medical research, economics, biostatistics, law, public policy, public health, and the allied health professions, as well as current and former executives from the pharmaceutical, hospital, and health insurance industries. The authors found major deficiencies in the current FDA system for ensuring the safety of drugs on the American market. Overall, the authors called for an increase in the regulatory powers, funding, and independence of the FDA. Some of the committee's recommendations were incorporated into drafts of the PDUFA IV amendment, which was signed into law as the Food and Drug Administration Amendments Act of 2007. As of 2011, Risk Minimization Action Plans (RiskMAPS) have been created to ensure risks of a drug never outweigh the benefits of that drug within the post-marketing period. This program requires that manufacturers design and implement periodic assessments of their programs' effectiveness. The Risk Minimization Action Plans are set in place depending on the overall level of risk a prescription drug is likely to pose to the public.
==== Syndiotactic polystyrene ==== Ziegler–Natta polymerization can produce an ordered syndiotactic polystyrene with the phenyl groups positioned on alternating sides of the hydrocarbon backbone. This form is highly crystalline with a Tm (melting point) of 270 °C (518 °F). Syndiotactic polystyrene resin is currently produced under the trade name XAREC by Idemitsu corporation, who use a metallocene catalyst for the polymerisation reaction.
Maffucci syndrome is a sporadic disease characterized by the presence of multiple enchondromas associated with multiple simple or cavernous soft tissue hemangiomas. Lymphangiomas may also be apparent. Patients are normal at birth and the syndrome manifests during childhood and puberty. The enchondromas affect the extremities and their distribution is asymmetrical.
Sources: en.wikipedia.org
==== Hydrides and halides ==== The hydride InH3 has at best a transitory existence in ethereal solutions at low temperatures. It polymerizes in the absence of bases. Lewis bases stabilize a rich collection of indium hydrides of the formula LInH3 (L = tertiary phosphine and N-Heterocyclic carbenes). Chlorination, bromination, and iodination of In produce colorless InCl3, InBr3, and yellow InI3. The compounds are Lewis acids, somewhat akin to the better known aluminium trihalides. Again like the related aluminium compound, InF3 is polymeric. Indium halides dissolves in water to give aquo complexes such as [In(H2O)6]3+ and [InCl2(H2O)4]+. Similar complexes can be prepared from nitrates and acetates. Overall, the pattern is similar to that for aluminium(III).
=== Fluorinated cyclooctynes === The cyclooctane derivative OCT was the first one developed for Cu-free click chemistry; it had only ring strain to drive the reaction forward, and the kinetics were barely improved over the Staudinger ligation. After OCT and MOFO (monofluorinated cyclooctyne), the difluorinated cyclooctyne (DIFO) was developed. An improved synthetic approach to a monofluorosubstituted cyclooctyne (MFCO) was introduced that could easily be converted to a useful reactive intermediate for bioconjugation applications, although the reactivity was somewhat slower than DIFO. The MFCO demonstrated excellent stability characteristics for long-term storage. The substituted cyclooctyne is activated for a 1,3-dipolar cycloaddition by its ring strain and electron-withdrawing fluorine substituents, which allows the reaction to take place with kinetics comparable to the Cu-catalyzed Huisgen cycloaddition. Ring strain (~18 kcal/mol) arises from the deviation of the bond angles from the ideal 180° to form an eight-membered ring, the smallest of all cycloalkynes. The electron-withdrawing fluorine substituents were chosen due to their synthetic ease and compatibility with living biological systems. Additionally, the group cannot produce cross-reacting Michael acceptors that could act as alkylating agents toward nucleophilic species within cells. Like most cyclooctynes, DIFO prefers the chair conformation in both the ground state and the minimum energy traction path, although boat transition states may also be involved.
== Impact on function == Conservative replacements in proteins often have a better effect on function than non-conservative replacements. The reduced effect of conservative replacements on function can also be seen in the occurrence of different replacements in nature. Non-conservative replacements between proteins are far more likely to be removed by natural selection due to their deleterious effects.
Sources: en.wikipedia.org
No, it is a synthetic peptide fragment corresponding to a small portion of hGH. It is not the full 191-amino-acid hormone and does not reproduce all of hGH's effects.
It is commonly described as a 16-amino-acid peptide based on residues 176-191 of human growth hormone. Some sources vary in notation, so checking the stated sequence is useful.
It is not typically described as a standalone natural hormone. The sequence is derived from the C-terminal region of human growth hormone, but the synthetic peptide is a laboratory-made construct.
It is a synthetic peptide based on a C-terminal fragment of human growth hormone. It is commonly referred to as hGH fragment 176-191 and is studied for metabolic effects rather than growth effects.